ArticleRespirology case reports2025
Relapse of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Despite Maintenance Treatment With Low-Dose Mepolizumab.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Steroid-Free Remission of Eosinophilic Granulomatosis With Polyangiitis Achieved With Low-Dose Mepolizumab: A Case Report.Clinical case reports · 2026Article
- Case Report: From misdiagnosis to successful treatment using mepolizumab in ANCA-negative severe EGPA-clinical lessons in eosinophil-targeted therapy.Frontiers in medicine · 2026Article
- Biomarker-guided IL-5 blockade achieves steroid-free MPO-ANCA seroconversion in EGPA.The journal of allergy and clinical immunology. Global · 2026Article
- Glucocorticoid-free remission with simultaneous mepolizumab and rituximab in life-threatening PR3-ANCA-positive eosinophilic granulomatosis with polyangiitis: a case report and literature review.Clinical rheumatology · 2026Review
- From Anti-Neutrophil Cytoplasmic Antibody-Negative to Positive: Eosinophilic Granulomatosis with Polyangiitis Under Benralizumab After Steroid Cessation.Journal of clinical practice and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of an ANCA+ EGPA patient with a long disease history and remission for over 8 years (between 2015 and 2023), who developed a life-threatening relapse marked by diffuse alveolar haemorrhage and mononeuritis multiplex despite low dose mepolizumab (100 mg q4w) maintenance therapy. She was treated with pulse dose corticosteroids, rituximab, and mepolizumab at an increased dose of 300 mg q4w. This treatment regimen led to clinical and serological improvement, but she has persistent neuropathic pain and reduced handgrip strength. Use of low dose mepolizumab in high risk EGPA patients (i.e., life-threatening disease, prior organ involvement) might be insufficient to prevent relapses causing permanent organ damage such as sensory or motor paralysis. It is important to take into account the EGPA phenotype based upon ANCA serology as well as type and severity of organ involvement, as these characteristics might be associated with different treatment requirements and responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.